BB Biotech AG : Un T2 en recul après un bon début d’année
>Une perte nette de 87 MCHF sur le T2 - BB Biotech publie ce matin ses chiffres du T2 2024. Le cours de la holding a reculé sur la période de 12% en CHF et de 11.3% en €. La performance de son portefeuille même si elle est de meilleure facture par rapport au cours ressort en territoire négatif à -3.5% en CHF, -2.6% en € et -3.3% en USD sous-performant l’indice de référence le Nasdaq Biotech Index (+2.8% en $ sur la période). Il en ressort une perte nette de -87 MCHF c...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.